Introduction {#S1}
============

Nicotinamide adenine dinucleotide (NAD) is a vital metabolic redox co-enzyme found in eukaryotic cells and is necessary for over 500 enzymatic reactions. It plays a crucial role in various biological processes, including metabolism, aging, cell death, DNA repair, and gene expression ([@B139]; [@B129]). Thus, NAD+ is critical for human health and longevity.

The co-enzyme was first discovered by Harden and Young in 1906 as a component that enhanced the rate of alcohol fermentation in yeast extracts ([@B66]). Over subsequent years, the chemical composition of the co-enzyme was established as an adenine, a reducing sugar group and a phosphate by Hans von Euler-Chelpin ([@B176]). Then, in 1936, Warburg suggested that NAD+ could play a role in redox reactions ([@B183]). By 1960, it was assumed that all biochemical investigations on NAD+ had been exhausted. In 1963, Chambon and Mandel reported that NAD+ is a co-substrate for the addition of poly-ADP-ribose to proteins, and this prompted a series of studies on poly-ADP ribose and poly-ADP-ribose polymerases (PARPs) ([@B26]; [@B197]). In the last decade, new interests in NAD+ emerged because of its association with sirtuins, a family of NAD-dependent protein deacylases (SIRT1--7) ([@B139]). Roy Frye showed that mammalian sirtuins could metabolize NAD+ and that NAD+ had a protein ADP-ribosyltransferase activity ([@B49]). Guarente and Imai made a phenomenal discovery that yeast SIR2 (silent information regulator 2) and the mouse ortholog SIRT1 have NAD+-dependent protein deacetylase activity ([@B74]). Previously, several studies had shown that sirtuins play a critical role in regulating multiple cellular functions, such as cell growth, energy metabolism, stress resistance, inflammation, and circadian rhythm neuronal function, among others ([@B76]; [@B139]). The deficiency of NAD+ is closely associated with diverse pathophysiologies, including type 2 diabetes (T2D), obesity, heart failure, Alzheimer's disease (AD), and cerebral ischemia. The NAD+ levels decline in multiple organs with age, and this contributes to the development of various age-related diseases ([@B198]; [@B56]; [@B123]; [@B117]). Therefore, NAD+ supplementation could be an effective therapy for the treatment of the conditions mentioned above.

Nicotinamide mononucleotide (NMN) is one of the intermediates in NAD+ biosynthesis and is a bioactive nucleotide formed by the reaction between a phosphate group and a nucleoside containing ribose and nicotinamide (NAM) ([@B134]). NAM is directly converted to NMN by nicotinamide phosphoribosyltransferase (NAMPT). The molecular weight of NMN is 334.221 g/mol ([@B134]). There are two anomeric forms of NMN named alpha and beta, and the latter is the active form ([@B134]). NMN is found in various types of natural foods, such as vegetables, fruits, and meat. Edamame and broccoli contain 0.47--1.88 and 0.25--1.12 mg NMN/100 g, respectively, whereas avocado and tomato contain 0.36--1.60 and 0.26--0.30 mg NMN/100 g, respectively. However, raw beef only contains 0.06--0.42 mg NMN/100 g ([@B117]). Recent preclinical studies have demonstrated that the administration of NMN could compensate for the deficiency of NAD+, and NMN supplementation was able to effect diverse pharmacological activities in various diseases.

In this review, NAD+ biosynthesis pathways and the possible reason for its age-related decline are described. Also, a summary of studies on the role of NAD+ deprivation in causing human diseases and how the application of NMN could have positive effects on those diseases is provided.

NAD+ Biosynthesis Pathways {#S2}
==========================

Three different NAD+ biosynthesis pathways have been described in mammalian cells ([Figure 1](#F1){ref-type="fig"}): (1) Preiss--Handler, in which NAD is synthesized from nicotinic acid (NA); (2) *de novo* synthesis, which starts from tryptophan; and (3) salvage pathway, which is most predominant in mammalian cells.

![Biosynthetic pathways of NAD+ in mammalian cells includes *de novo*, Preiss--Handler, and salvage pathways, and the salvage pathway is the main source of NAD+. NAD, nicotinamide adenine dinucleotide; NA, nicotinic acid; NAPRT, nicotinic acid phosphoribosyltransferase; NAMN, nicotinic acid mononucleotide; NAAD, nicotinic acid adenine dinucleotide; NADS, NAD+ synthetase; NMNAT, nicotinamide/nicotinic acid mononucleotide adenylyltransferase; ACMS, 2-amino-3-carboxymuconate semialdehyde; QA, quinolinic acid; QPRT, quinolinate phosphoribosyltransferase; NAM, nicotinamide; NAMPT, nicotinamide phophoribosyltransferase; NMN, nicotinamide mononucleotide; NR, nicotinamide riboside; NRK, nicotinamide riboside kinase.](fcell-08-00246-g001){#F1}

The Preiss--Handler Pathway {#S2.SS1}
---------------------------

This pathway starts with conversion of NA to the nicotinic acid mononucleotide (NAMN) by the enzyme nicotinic acid phosphoribosyltransferase (NAPRT) ([@B135]). Afterward, NAMN is used for nicotinic acid adenine dinucleotide (NAAD+) biosynthesis by nicotinamide/nicotinic acid mononucleotide adenylyltransferase (NMNAT1/2/3). Finally, NAD+ synthetase (NADS) transforms NAAD+ to NAD+ with ammonia and ATP action as extra ingredients ([@B194]).

*De novo* Synthesis From Tryptophan {#S2.SS2}
-----------------------------------

The eight-step *de novo* synthesis pathway is initiated by indoleamine 2,3-dioxygenase (IDO) or tryptophan 2,3-dioxygenase (TDO) that convert tryptophan to *N*-formylkynurenine ([@B149]). Through formamidase (KFase), *N*-formylkynurenine is then transformed to be kynurenine, to which hydroxyl is added via kynurenine 3-hydroxylase (K3H). The product, 3-hydroxy-kynurenine, is converted to 3-hydroxyanthranilate followed by 2-amino-3-carboxymuconate semialdehyde (ACMS) via kynureninase (Kyase) and 3-hydroxyanthranilate-3,4-dioxygenase. ACMS then cyclizes to form quinolinic acid (QA) that participates in NAMN biosynthesis with quinolinate phosphoribosyltransferase (QPRT) ([@B194]). The last two steps are the same as the Preiss--Handler pathway that NAD+ is synthetized sequentially from NAMN and NAAD by NMNAT 1/2/3 and NADS.

The Salvage Pathway {#S2.SS3}
-------------------

The salvage pathway is the primary source of NAD+ in mammalian cells. The degradation of NAD+ and subsequent generation of NAM (as a by-product) are achieved by NAD-consuming enzymes, such as sirtuins, PARPs, CD38, CD157, and sterile alpha and TIR motif-containing protein 1 (SARM1) ([@B129]). There are only two steps in the salvage pathway. The rate of NAD+ synthesis in this pathway is mostly determined by NAMPT that converts NAM and 5-phosphoribosyl-1-pyrophosphate (PRPP) to NMN in the first step. Then, NMN, the substrate for NAMNT, is conjugated to ATP and converted to NAD in the second step.

The NAMPT exists in two forms in mammals, that is, intracellular NAMPT (iNAMPT) in the cytoplasm and nucleus and extracellular NAMPT (eNAMPT) in the plasma or extracellular space ([@B145]). The SIRT1-dependent deacetylation of iNAMPT predisposes the protein to secretion in adipocytes ([@B196]). Various types of cells, including mature adipocytes, pancreatic β-cells, myocytes, epithelial cells, and hepatocytes ([@B145]; [@B52]; [@B207]) secrete and release eNAMPT to the plasma or extracellular space.

Also, another NAD precursor, nicotinamide riboside (NR), is incorporated into cells using equilibrative nucleoside transporters (ENTs) ([@B128]) and phosphorylated to NMN by nicotinamide riboside kinase (NRK1/2) intracellularly ([@B141]). Conversion of extracellular NMN to NR mediated by enzyme CD73 is required for cell uptake and intracellular synthesis of NAD+ ([@B60]; [@B141]). NAD+ biosynthesis in kidney and brown adipose tissue has been shown to decrease after administration of NMN in NRK1 knockout mice ([@B141]). However, a recent study identified Slc12a8 as a specific transporter of NMN, which is highly expressed in the small intestine ([@B59]). In the study, Slc12a8 expression was upregulated in the small intestines of aged mouse in response to a decrease of NAD+. These findings suggested that the uptake pathway of NMN could be via a cell- or tissue-specific manner.

Given that the salvage pathway is the main and the most efficient route for NAD+ biosynthesis, NMN or NR supplementation is becoming the preferred option of improving NAD+ levels that is devoid of side effects. Currently, increasing numbers of clinical trials using NMN and NR have been approved and are geared toward the treatment of various diseases, which further demonstrate that NMN is a suitable and safe drug for use in humans.

Effect of Aging on NAD+ Levels {#S3}
==============================

NAD+ Biosynthetic Pathways Decline With Age {#S3.SS1}
-------------------------------------------

The decline in NAD+ biosynthetic pathways in the course of aging could be a possible explanation for the reduction of NAD+ levels. NAMPT controls NAD+ levels, thereby influencing the activity of NAD-dependent enzymes, including sirtuins and PARPs.

A study demonstrated that the NAD+ levels and NAMPT protein levels declined significantly in multiple organs, including the pancreas, white adipose tissue (WAT), and skeletal muscle of old mice ([@B198]). However, exercise training increased NAMPT expression in the skeletal muscles ([@B33]). NAD+ levels and exercise capacity were preserved in aged transgenic mice with muscle-specific NAMPT transgene expression ([@B48]). These results suggested that the deficiency of NAMPT result in a reduction of NAD+ levels in the aged mice, and exercise may elevate NAMPT expression, thus restoring the NAD+ levels ([Figure 2](#F2){ref-type="fig"}).

![Hypothetic molecule mechanisms of NAD+ decreased with aging. Oxidative stress, DNA damage, and chronic inflammation are increased with aging, which results in accelerated NAD degradation via activation of CD38 and PARPs, or dysregulation of NAMPT. Finally, decreased levels of NAD+ lead to various metabolic and age-associated diseases.](fcell-08-00246-g002){#F2}

Inflammation and oxidative stress caused by aging have been shown to reduce the NAMPT-mediated NAD+ biosynthesis ([@B198]; [Figure 2](#F2){ref-type="fig"}). Besides, *Nampt* gene encoding is controlled by BMAL1/CLOCK complex, a heterodimeric complex of core circadian transcription factors, which is suppressed by inflammatory cytokines ([@B23]). Therefore, the development of chronic inflammation in the course of aging may contribute to the inhibition of NAMPT-mediated NAD+ biosynthesis and CLOCK/BMAL-mediated circadian machinery ([@B75]).

NAD+-Consuming Enzymes Are Activated With Age {#S3.SS2}
---------------------------------------------

### PARP1 {#S3.SS2.SSS1}

PARPs were initially considered to be DNA damage repair agents in the 1960s ([@B29]). The accumulation of DNA damage during aging could activate PARP, among which PARP-1 acts as a major cellular NAD+-consuming enzyme ([@B75]). Cockayne syndrome (CS) is an aging-related progressive neurodegeneration that occurs as a result of mutations in either Cockayne syndrome group A (CSA) or B (CSB) proteins ([@B54]; [@B152]). In CS mice, PARP inhibitor or NAD+ supplementation reversed decline in SIRT1 activation and mitochondrial function caused by aberrant PARP activation ([@B152]). Consistently, another inhibitor of PARP, PJ34, or knockout boosted the levels of NAD+, SIRT1 activity, and oxidative metabolism ([@B7]).

### CD38 {#S3.SS2.SSS2}

The CD38 enzyme and its homolog CD157 were initially described as plasma membrane antigens on thymocytes and T lymphocytes. Their role in NAD+ consumption have been revealed; that is, CD157/BST-1 could hydrolyze NR ([@B136]) and CD38 hydrolyzes NAD+ to generate NAM, adenosine diphosphoribose (ADPR), and cyclic ADPR (cADPR). In addition, CD38 also hydrolyzes cADPR ([@B35]) and NMN ([@B60]).

In mammals, the level of NAD+ and mitochondrial function decreased partially through regulation of SIRT3 as the expression and activity of CD38 protein increased in various tissues during aging ([@B19]). Administration of CD38 inhibitors elevated intracellular NAD+ level ([@B43]; [@B16]). Consistently, CD38 knockout mice displayed significantly higher NAD+ level in multiple organs ([@B199]).

### Sterile Alpha and TIR Motif-Containing 1 (SARM1) Protein {#S3.SS2.SSS3}

The toll/interleukin-1 receptor (TIR) domain of sterile alpha and TIR motif-containing 1 (SARM1) protein presents NADase activity ([@B139]) that is involved in axonal degeneration after axon injury. In response to neuronal injury, the TIR domain of SARM1 cleaves NAD+ to generate ADP ribose (ADPR) and cyclic ADPR, which may contribute to axonal degeneration ([@B45]). Paradoxically, overexpression of enzymes in NAD+ biosynthesis pathway or supplying NR could inhibit SARM1-induced axon destruction ([@B53]).

In summary, there are many ways of restoring NAD+ level depletion caused by aging or other diseases, including improving NAMPT expression, providing NAD+ precursors, or inhibiting NAD+, consuming enzymatic activities of PARP, CD38, and SARM1. Currently, supplementation with NMN or NR is considered a viable and highly efficient strategy of increasing NAD+ levels ([Figure 3](#F3){ref-type="fig"}).

![Nicotinamide mononucleotide exerts pharmacological effects by increasing intracellular NAD+ levels. Extracellular NMN is cleavage by CD73, which yields NR that is incorporated into cells using equilibrative nucleoside transporters (ENTs). NMN is converted to NAD+, which produces beneficial effects on cell, including mitochondrial function, DNA repair, gene expression, anti-inflammation and cell survival.](fcell-08-00246-g003){#F3}

Diabetes {#S4}
========

The global prevalence of diabetes has increased dramatically over the past four decades. According to the WHO report, the number of people with diabetes rose from 108 million in 1980 to 422 million in 2014. T2D is characterized by insulin resistance and subsequent impairment of insulin secretion ([@B129]). The metabolism of NAD+ plays a crucial role in insulin sensitivity and secretion and is sometimes disrupted by obesity and aging.

Revollo et al. showed that eNAMPT was necessary for NAD+ biosynthesis ([@B145]). Declined NAD+ levels and glucose-stimulated insulin secretion (GSIS) in pancreatic β cells and impaired glucose tolerance were observed in Nampt^+/--^ mice. Similar blood glucose and plasma insulin levels were observed in Nampt^+/--^ and control mice after NMN (i.p. 500 mg/kg) treatment. Also, FK866, an inhibitor of NAMPT, reduced NAD+ levels, and glucose-stimulated insulin secretion in primary islets, whereas NMN treatment reversed the defects ([@B145]). These results demonstrated that Nampt-mediated NAD+ biosynthesis is critical for β cell function, and that NMN treatment can ameliorate the deficiency in NAD biosynthesis and glucose-stimulated insulin secretion.

Obesity and diabetes are inextricably linked. MicroRNAs (miRNAs) are key regulators of metabolism, by which SIRT1 expression is regulated in healthy conditions and metabolic diseases ([@B99]). In the dietary obese mice, the elevation of hepatic microRNA-34a (miR-34a) inhibited the expression of NAMPT and SIRT1, which was responsible for the decrease in NAD+ levels and SIRT1 activity ([@B30]). The reduction of SIRT1 activity resulted in transcriptional responses of decreased fatty acid β-oxidation and increased lipogenesis and inflammation ([@B30]). Mice overexpressing miR-34a were intraperitoneally injected with NMN (500 mg/kg) for 10 days consecutively, the effects caused by hepatic overexpression of miR-34 were reversed, and glucose tolerance was enhanced ([@B30]). These results suggested that NMN could be a potential agent for the treatment of obesity-associated T2D involving SIRT1 dysfunction.

Because of the high intake of dietary sugar, the risk of metabolic syndrome and T2D has been on the increase in humans ([@B114]). Fructose consumption contributes to the development of pro-inflammatory effect in rodent models, which is involved in the process of insulin resistance and the onset of T2D ([@B147]). Fructose-rich diet (FRD) results in T2D-like symptoms, including hyperglycemia, dyslipidemia, and inflammation ([@B147]). FRD-fed mice showed an increased expression of IL-1b and TNF-α, which are pro-inflammatory phenotypes. The GSIS and leucine-stimulated insulin secretion (LSIS) were significantly reduced in FRD-fed mice, which was associated with islet dysfunction caused by a decrease of eNAMPT in plasma, whereas the administration of NMN at the dose of 500 mg/kg eliminated the adverse effects of FRD on GSIS and LSIS in mice ([@B22]).

FRD increased the expression of Inos (induces cellular stress and cell death) and Bax (pro-apoptotic gene) genes and reduced the expression of Pdx1, Glut2, and Gk genes, which are all essential for glucose detection and beta-cell differentiation. These changes in gene expression were restored by NMN treatment. Moreover, the decrease in expression of Sirt1 and Sirt3 genes in FDR mice were reversed by NMN treatment. These results suggested that NMN could improve islet function by influencing the expression of genes related to anti-inflammatory, islet beta-cell differentiation, and SIRT1 activation.

Yoshino et al. revealed that the administration of NMN was highly effective in combating diet- and age-induced T2D ([@B198]). In their study, mice fed with high-fat diet (HFD) displayed significantly reduced NAMPT protein and NAD+ levels in the liver and WAT and not in skeletal muscle as was expected. The HFD-induced male and female diabetic mice after receiving intraperitoneal administration of NMN (500 mg/kg/day) for 10 and 7 consecutive days, respectively, exhibited restored NAD+ levels in the liver and WAT. Impaired glucose and insulin tolerance were significantly improved in diabetic female mice. The effect of NMN in reversing impaired glucose tolerance was milder in males compared to females, and insulin tolerance remained unchanged in male mice.

Yoshino et al. also confirmed that NMN improves hepatic insulin sensitivity by reversing the expression of genes related to oxidative stress, inflammatory response, immune response, and lipid metabolism ([@B198]). For example, the expression of the glutathione *S*-transferase alpha two gene (Gsta2), which is crucial for the maintenance of hepatic insulin by protecting lipid peroxidation products, was suppressed by HFD but activated by NMN. Other genes that are related to insulin resistance were significantly influenced by NMN in HFD-induced mice, such as interleukin 1β, lipin1, and pyruvate dehydrogenase kinase 4 (Pdk4). Also, Yoshino et al. revealed that SIRT1 was responsible for gene expression dynamics, and its suppression by HFD was restored by NMN.

Aging is one of the highest risk factors for developing T2D ([@B120]). Previous studies have shown that progressive decline in β cell function in the course of aging contributes to the pathophysiology of T2D ([@B9]). As mentioned above, NAD+ and NAMPT levels declined during aging ([@B198]). Administration of NMN (500 mg/kg/day) for 11 consecutive days resulted in significant improvement in glucose tolerance and utilization in aged mice. Also, hyperlipidemia induced by HFD was also reversed by this treatment. Meanwhile, NMN did not have other effects on glucose homeostasis in non-diabetic old mice ([@B198]). [@B117] also demonstrated that long-term (12 months) administration of NMN ameliorated age-associated decreased insulin sensitivity. Triglyceride levels in the liver were lower after 12-month NMN administration, which indicated a decline in insulin resistance. Mice that were put on long-term NMN intervention showed a tendency of plasma fatty acids (FFA), which is consistent with improved insulin sensitivity ([@B117]).

[@B124] reported that an increase in Sirt1 dosage in pancreatic β cells improved GSIS and glucose tolerance in beta cell-specific Sirt1-overexpression (BESTO) transgenic mice at 3 and 8 months of age. However, the same cohort of BESTO mice did not show these beneficial effects at 18--24 months of age ([@B140]). It has been reported that Sirt1 improves glucose-stimulated insulin secretion through the repression of Ucp2 and improvement of ATP levels in pancreatic β cells ([@B15]; [@B140]), which was abolished in aged mice, resulting in maintenance of a high level of Sirt1 protein. Also, NMN plasma levels declined significantly in aged BESTO mice, which suggested that a decrease in Sirt1 activity and loss of the glucose-responsiveness in BESTO mice resulted from the decline in systemic NAD biosynthesis. Thus, intraperitoneal injection of NMN (500 mg/kg) into 20-month-old BESTO mice led to an enhancement in GSIS and improvement in glucose tolerance in the aged BESTO females instead of males.

Generally, these discoveries demonstrated that NMN could be a promising drug for obese-associated and age-induced T2D through the role it plays in the enhancement of NAD+ biosynthesis and Sirt1 activity.

Obesity {#S5}
=======

Obesity is associated with insulin resistance in multiple organs. It is a systemic metabolic derangement, which is involved in the pathogenesis of many diseases such as T2D, non-alcoholic fatty liver disease (NAFLD), atherogenic dyslipidemia, and cardiovascular disease ([@B142]). It has been reported that the dysfunction of adipose tissue could result in obesity-associated metabolic disorders in multiple organs because adipose tissue has effects on maintaining the functional integrity of whole-body metabolic health ([@B164]). Significantly reduced iNAMPT has been manifested in adipocyte as a result of HFD ([@B198]; [@B24]), however, elevated eNAMPT was detected in obesity ([@B21]). Compared with clear function of iNAMPT in NMN synthesis, the significance of eNAMPT is controversial. In response to cellular stress, nutritional cues, or inflammatory cytokines, adipocytes secreted eNAMPT through PI3K-AKT pathway ([@B65]), SIRT1-mediated pathway ([@B196]), or other unknown pathway ([@B167]). The role of eNAMPT has been indicated to be inflammatory promotion, inflammatory suppression ([@B145]; [@B103]; [@B133]; [@B204]; [@B80]), enhancement of food intake ([@B18]), and regulation of insulin resistance as well as plasma free fatty acid concentration ([@B164]; [@B127]). The function of eNAMPT remains elusive in recent research, demonstrating that low concentration of dimeric eNAMPT benefited for beta cell function through NAD+, however, a higher monomeric eNAMPT level presented hostile effect on beta cell function ([@B151]). Obesity has also been associated with the dampened NAD+/SIRT pathway in adipose tissue ([@B82]). These findings suggested that NAMPT-mediated NAD+ biosynthesis in adipose tissue could be involved in the regulation of whole-body glucose metabolism.

Adipocyte-specific Nampt knockout (ANKO) mice showed a severe multi-organ insulin resistance, including adipose tissue, liver, and skeletal muscle, independently with an increase in whole-body adiposity and weight. The plasma FFA availability and local adipose tissue inflammation were also increased in the ANKO mice ([@B164]). The plasma concentration of two key adipokines, namely, adiponectin and adipsin, were significantly reduced in ANKO mice. It has been reported that adiponectin and adipsin regulate insulin sensitivity and glucose homeostasis ([@B83]). Phosphorylation of cyclin-dependent kinase 5 (CDK5) and peroxisome proliferator-activated receptor γ (PPARγ) was increased in adipose tissue of the ANKO mice, which led to a significant decline in gene expression of obesity-linked specific targets of phosphorylated PPARγ, including adiponectin and adipsin. As was expected, NAD+ levels in adipose tissue from the ANKO mice were significantly increased after oral administration of NMN (500 mg/kg) for 4--6 weeks. The NMN treatment also improved multi-organ insulin sensitivity and normalized plasma insulin and FFA concentrations in the ANKO mice. Moreover, the phosphorylation of PPARγ (Ser273) and CDK5 in visceral adipose tissue (VAT) was reduced by the NMN treatment. Accordingly, the plasma concentrations and gene expression of adiponectin and adipsin in adipose tissue were enhanced ([@B164]). Therefore, these results provided evidence that NMN could be a therapeutic molecule for obesity-associated systemic metabolic derangements, particularly multi-organ insulin resistance. ANKO and brown adipocyte-specific Nampt knockout (BANKO) mice both showed impaired gene programs involved in thermogenesis, mitochondrial biogenesis, and FFA metabolism in BAT ([@B192]). However, only ANKO mice have a blunted thermogenic response (lower temperature in rectal and BAT, and whole-body oxygen consumption) to acute cold exposure, fasting, and administration of β-adrenergic agonists. Altered function in WAT may contribute to this difference. Lack of NAMPT in WAT decreased adrenergic-mediated lipolysis through inactivation of the NAD+--SIRT1--caveolin-1 axis, which reduced the release of FFAs as fuel source for BAT thermogenesis. NMN administration normalized these metabolic abnormalities, including increasing BAT NAD+ levels, decreasing BAT weight and BAT whitening as well as restoring gene expression of caveolin-1 in WAT and those involved in thermogenesis, mitochondrial function, and FFA metabolism in BAT. Moreover, ANKO mice treated with NMN showed greater cold tolerance compared with ANKO mice ([@B192]).

Several studies have confirmed that physical exercises have various health benefits, especially in obesity-related cases ([@B175]; [@B148]), which, in part, results from the upregulation of mitochondrial activity because of increased NAD levels. Mouse models showed that NAD+ levels in metabolic organs and mitochondrial biogenesis could be improved by physical exercises ([@B148]). Thus, taking physical exercises is thought to be an effective way of increasing NAD+ levels. To compare the efficiency of increasing NAD+ levels between NMN supplementation and exercise, HFD-induced obese mice were given NMN (500 mg/kg) for 17 days or treadmill running (45 min/day) was implemented for 6 days per week for 6 weeks. According to the results, NMN treatment increased NAD+ levels in muscles and the liver, but exercise increased NAD+ levels in muscles only. The liver mass and triglyceride content were significantly reduced, and citrate synthase activity was increased after NMN treatment in HFD-fed mice, which suggested that NMN could increase catabolism of fats. Exercises and NMN have a similar effect on glucose intolerance induced by obesity, however, these two interventions are tissue-specific with a different impact on mitochondrial function in muscles and the liver ([@B174]). [@B173] also showed that NMN could reduce the effects of maternal obesity as compared to exercise. Maternal overnutrition is often associated with increased infant birth weight, adiposity, and high risk of long-term obesity in later life of the offspring ([@B20]). Thus, it is important to investigate new strategies for reducing the risk in future generations. A study found that treadmill exercise (for 9 weeks) and NMN injection (for 15 days) both reduced adiposity and improved glucose tolerance and mitochondrial function. Moreover, NMN showed stronger effects on liver fat catabolism and synthesis than exercise. This study suggested that NMN treatment might be an effective option for reversing negative effects caused by maternal obesity ([@B173]).

Long-term administration of NMN can significantly reduce age-associated body weight gain in a dose-dependent manner. A study conducted a 12-month-long administration of NMN (from 5 to 17 months) in mice. The results indicated that the 100- and 300-mg/kg dose of NMN was able to reduce the mice's weight by 4 and 9%, respectively, compared to the control mice. No difference was observed in body length between NMN-treated and control mice. NMN-treated mice also maintained higher levels of food and water consumption compared to control mice, which suggested that NMN did not cause severe side effects, such as growth defect and loss of appetite ([@B117]). In conclusion, the administration of NMN could be an effective option for maintaining body weight and reversing metabolic dysfunctions caused by obesity.

Ischemia--Reperfusion Injury {#S6}
============================

Ischemia is known to decrease oxygen and ATP levels in tissues, leading to cell necrosis. Reperfusion is a reoxygenation process whereby blood re-enters a previously ischemic tissue, and this often causes calcium overload and production of ROS ([@B150]). Ischemia followed by reperfusion has been reported to trigger severe tissue damage, for which ischemic preconditioning (IPC) is a confirmed preventative strategy ([@B150]).

It has been reported that activation of SIRT1 can protect the heart from ischemia and reperfusion (I/R)-induced injury ([@B72]). SIRT1 upregulates cardioprotective molecules, such as MnSOD (antioxidants), Trx1 (antioxidants), and Bcl-xL (anti-apoptotic), while it decreases pro-apoptotic molecules, including Bax and cleaved caspase-3. FoxO1, a transcription factor deacetylated by Sirt1, partially mediates the SIRT1-induced upregulation of MnSOD ([@B72]), which protects the heart from oxidative stress. Moreover, maintaining NAMPT expression is critical for prevention of myocardial injury caused by I/R ([@B71]). The deacetylase activity of SIRT1 is dependent on NAD+. Thus, enhancing NAD+ may promote SIRT1-mediated IPC.

NMN has been shown to confer protection on the heart in ischemic and reperfusion conditions ([@B193]). Yamamoto et al. found that IPC upregulates NAMPT and the protective effect of IPC on heart during I/R injury is attenuated in Nampt^+/--^ mice, suggesting that NAMPT mediates the protective effect of IPC. The NAD+ levels in heart were decreased after 30 min of ischemia and transiently normalized by NMN administration. Implementation of two patterns of NMN administration, once 30 min before ischemia or 4 times repetitive administration just before and during reperfusion, reduced the infarct size by 44 and 29%, respectively. However, a single administration of NMN 12 h before ischemia and once immediately before reperfusion did not significantly reduce the infarct size. These findings suggest that NMN reduces infarct size after by I/R, and this effect is timing-dependent. Notably, NMN attenuated the increase in acetylation of FoxO1 during myocardial ischemia, but NMN failed to reduce the infarct size in Sirt1-KO mice, indicating that the protective effect of NMN on the heart following I/R injury is partly mediated by Sirt1.

NMN suppressed cardiomyocyte apoptosis in the peri-infarct area after I/R and significantly improves left ventricle (LV) systolic function caused by I/R. In addition, NMN activates autophagy during myocardial ischemia, which is consistent with the finding that NAMPT and SIRT1 promote autophagy in cardiomyocytes ([@B71]). An *ex vivo* experiment showed that NMN attenuated myocardial I/R injury in aged rats ([@B69]). Rats treated with NMN showed improved myocardial function and reduced infarct size. Besides, NMN exerted positive effects on mitochondrial function by improving the antioxidant system, restoring oxidative stress, and reducing mitochondrial ROS production and membrane depolarization. Importantly, the combination of NMN and melatonin could produce stronger cardioprotection.

Glycolytic stimulation during ischemia and enhanced acidosis during reperfusion are additional mechanisms for NMN-induced cardioprotection ([@B126]). Under normal conditions, cardiac ATP production is executed by β-oxidation of fatty acids ([@B159]). Generating ATP via glycolysis is usually considered a manifestation of cardiac pathology and heart failure ([@B159]). However, recent studies show that glycolysis has cardioprotective effects ([@B55]). Nadtochiy et al. reported that NMN stimulates glycolysis and increases ATP production during ischemia, which partially contributes to NMN-induced cardioprotection ([@B126]). IR injury triggers the opening of the mitochondrial permeability transition pore (mPTP). Acid pH maintains the closed state of PT pores during ischemia, however, changes in pH during reperfusion promote mitochondrial pore opening ([@B58]). Addition of acidic media offers cardioprotection by maintaining the closed state of PT pore in early reperfusion ([@B31]). It is worth noting that acidosis may promote mPTP in energetic mitochondria by stimulating Pi uptake ([@B95]). NMN elevates cardiac lactate and pyruvate to induce acidosis, which protects against IR-induced injury ([@B126]).

[@B130] showed that NMN antagonizes global cerebral ischemia injury. Ischemic insults increase the production of free radicals, which causes DNA oxidative damage and PARP1 activation, and uncontrolled PARP1 activation decreases NAD+, which further decreases ATP synthesis, leading to cell death ([@B165]). Conversely, NMN maintains normal cellular NAD+ levels by inhibiting the NAD+ catabolism of PARP1 to improve bioenergetics metabolism of post-ischemic tissue and ameliorate brain damage. NMN treatment at 30 min after initiation of reperfusion reduces hippocampal CA1 neuron cell death and improves ischemia-induced hippocampal dysfunction involved in spatial working memory ([@B130]). The NAD+ levels in hippocampal tissue are significantly reduced after forebrain ischemia, and NMN inhibits this decrease in NAD+. Meanwhile, studies show that hippocampal PARP protein levels are significantly increased in mice with cerebral ischemia, accompanied by elevated ROS production. Interestingly, this effect is blocked by administration of NMN at the start of reperfusion. Notably, when administered at a dose of 62.5 mg/kg, NMN produced optimal treatment effects compared to other doses (500, 250, 125, and 31.25 mg/kg), suggesting that high dosage of NMN may introduce adverse effects on post-ischemic neurons. In fact, accumulation of NMN in nerve injury promotes axonal degeneration ([@B38]) and NMN deamidase delays Wallerian degeneration and rescues axonal outgrowth defects ([@B37]). Recently, [@B91] revealed a novel link between mitochondrial NAD+ metabolism, mitochondrial dynamics, and ROS production in cerebral ischemia. They showed that NMN treatment prevents post-ischemic depletion of mitochondrial NAD+, suppresses mitochondrial fragmentation, and reduces ROS generation via SIRT3-dependent mechanisms ([@B91]). The activity of superoxide dismutase 2 (SOD2), a key mitochondrial antioxidant enzyme, was inhibited by an increase in its acetylation after ischemia, which can be reversed by NMN treatment. Moreover, NMN also prevents ischemia-induced phosphorylation of mitochondrial fission Dynamin-related protein (Drp1) ([@B91]).

[@B179] have already demonstrated that NAMPT protected against ischemic stroke through promoting neuronal survival via the SIRT1-dependent AMPK pathway. As the NAMPT enzymatic product, NMN alleviates cerebral infarction size, neurological deficit, and neuronal cell death ([@B179]). Furthermore, the important role of NAMPT--NAD cascade in regenerative neurogenesis after ischemic stroke has been underscored by [@B206], and delayed NMN supplementation for 7 days with the first administration at 12 h after cerebral ischemia improved post-ischemic regenerative neurogenesis.

Heart Failure and Cardiomyopathies {#S7}
==================================

Heart failure is the end stage of heart disease development and refers to the inability of the heart to pump sufficient blood to match the metabolic requirements of tissues due to impaired systole and/or diastole. Generally, heat failure is always associated with enlarged heart and dilated ventricles ([@B132]).

Heart failure is one of diseases that are associated with mitochondrial respiratory dysfunction ([@B85]). It was found that deletion of Ndufs4, a protein critical for assembly and/or stability of complex I, resulted in a significant loss of complex I function in the heart. The cardiac-specific Ndufs4 KO (cKO) mice not only showed normal longevity and cardiac function in unstressed condition, but also exhibited normal myocardial energetics and contractile function during baseline workload or acute increases of workload. However, after chronic increases of workload including pressure overload and repeated pregnancy, the cKO mice with complex I deficiency developed heart failure and high cell death, and could not be explained by oxidative stress mechanism. Complex I deficiency significantly decreased NAD+/NADH ratio, which inhibited sirt3 activity, increased mitochondrial protein acetylation, and sensitized mPTP. Additionally, it has been shown that NMN treatment rescues NAD+/NADH ratio and mitochondria protein acetylation in cKO hearts, and normalizes the sensitivity of the mPTP ([@B85]).

Lee et al. reported that mitochondrial protein hyperacetylation, which is caused by elevated NADH/NAD+, increases the risk of development of heart failure by two distinct mechanisms ([@B98]). Malate aspartate shuttle (MAS) modulates communication between cytosolic and mitochondrial NAD+ redox states, transferring electrons from cytosolic NADH generated from glycolysis into mitochondria for oxidative phosphorylation ([@B96]; [@B98]). During mitochondrial dysfunction, hyperacetylation of MAS decreases cytosolic NAD+/NADH ratio, thereby inducing mPTP-related cell death and the development of heart failure ([@B42]). [@B98] also identified that the acetylation of lysine-70 on oligomycin-sensitive conferring protein (OSCP) sensitized mPTP opening by promoting its interaction with cyclophilin D (CypD), a regulator of mPTP. Thus, administration of NMN reverses hyperacetylation of these proteins by normalizing the NAD+ redox balance, thereby protecting mice from heart failure.

Kruppel-like factor 4 (KLF4) is critical for cardiac mitochondrial homeostasis. Accordingly, mice with cardiac-specific deficiency of KLF4 (CM-K4KO) are more sensitive to pressure overload-induced heart failure ([@B105]). Zhang et al. found that cardiac KLF4 deficiency led to hyperacetylation of mitochondrial proteins, including SOD2, CypD, and long-chain Acyl-CoA dehydrogenase (LCAD), which impaired mitochondrial metabolic function and predisposed the CM-K4KO hearts to stress-induced dysfunction ([@B202]). Meanwhile, the expression of Sirt3, NAD+, and NAMPT were reduced in the KLF4-deficient heart, all of which decreased deacetylase activity in the mitochondria. Moreover, NMN increased NAD+ levels and normalized the mitochondrial protein acetylation levels in cardiac tissue. Remarkably, NMN preserved the cardiac contractile function and protected CM-K4KO mice from heart failure during pressure overload. LCAD is a fatty acid oxidation (FAO) enzyme, which oxidizes long-chain fatty acid, the main fuel of heart. The activity of this enzyme is dependent on Sirt3-NAD+ deacetylation ([@B67]), and acute NMN treatment increased mitochondrial FAO, indicating that NMN improves cardiac energetics and heart function. CM-K4KO hearts showed high rates of cell death in myocardium when subjected to stress, and NMN administration prevented cell death in pressure-overloaded hearts. Finally, NMN was found to preserve the mitochondrial ultrastructure and reduce ROS and inflammation in CM-K4KO myocardium partially through Sirt3-dependent deacetylation and activation of SOD2 in response to oxidative stress ([@B202]). In summary, short-term administration of NMN may confer protection against cardiac mitochondrial homeostasis and prevent heart failure.

[@B115] reported that NMN improves cardiac function and bioenergetics in a SIRT3-dependent manner in a Friedreich's ataxia (FRDA) cardiomyopathy model, a mouse genetic cardiomyopathy model with frataxin-KO (Fxn^--/--^, FXN-KO). NMN (500 mg/kg) administered two times per week for 4--5 weeks improves diastolic function and normalizes the defective cardiac contractility in FXN-KO. A shortened ejection time (ET) represents impaired contractility or severe LV dysfunction in patients with heart failure or idiopathic-dilated cardiomyopathy ([@B41]). FXN-KO mice show a shortened ET, whereas NMN treatment significantly increases ET ([@B115]).

NMN supplementation also improves cardiac energy utilization and decreases energy wastage in the FXN-KO heart. Cardiac efficiency (CE), a ratio of energy used for mechanical work to overall energy available, is decreased in FXN-KO. Also, FXN-KO mice also shows an increased ventriculoarterial coupling (VC) ratio, another parameter representing the efficiency of converting ventricular mechanical energy (ME) into hydraulic energy in the aorta during systole ([@B166]; [@B177]). NMN treatment normalizes both CE and VC in the FXN-KO heart failure model. Pressure--volume area (PVA) is the sum of ME and potential energy (PE) ([@B166]). In FXN-KO hearts, a large proportion of PVA is consumed as PE, rather than ME, which indicates greater energy wastage in heart failure. However, NMN treatment improves myocardial energy utilization by normalizing the proportion of PE in PVA.

Additionally, the study reported that NMN-induced reduction in energy wastage paralleled the remarkable decrease in whole-body energy expenditure (EE) due to decreased FA metabolism and a SIRT3-dependent carbohydrate metabolism ([@B115]). FXN-KO mouse show elevated whole-body daily FA oxidation and serum triacylglycerides, while NMN supplementation blocks this elevation. Moreover, NMN reduces tissue lactate production and inhibits glycolysis by decreasing systemic and cardiac glucose utilization in the FXN-KO heart, thereby improving CE and function ([@B115]). Importantly, the therapeutic effects of NMN are mediated by deacetylation of SIRT3 in FXN-KO hearts ([@B115]). In summary, these findings provide preclinical evidence that NMN could be a promising drug for heart failure and cardiomyopathies.

Vascular Dysfunction {#S8}
====================

Cardiovascular disease (CVD) is the leading cause of mortality worldwide. Aging is a developmental risk factor for the disease. Vascular endothelial dysfunction and large elastic artery stiffness are two antecedents and predictors of clinical CVD ([@B118]). Vascular oxidative stress contributes to vascular endothelial dysfunction and large elastic artery stiffness ([@B6]). Excessive superoxide reduces the bioavailability of nitric oxide (NO), a vasoprotective, and vasodilatory molecule, and thus causes alterations of structural proteins such as collagen and elastin, in large elastic arteries ([@B153]). Vascular endothelial dysfunction and large elastic artery stiffness are assessed by endothelium-dependent dilation (EDD) and aortic pulse wave velocity (aPWV), respectively ([@B36]). Old mice showed impaired carotid artery EDD, and oral supplement of NMN (300 mg/kg) for 8 weeks restored EDD in the old mice by assisting in regaining NO-mediated dilation and reducing arterial oxidative stress ([@B36]). Also, NMN restored the expression and activity of the SIRT1 in the arteries of old mice in accordance with previous studies, which revealed that the reduced expression and activity of SIRT1 contributes to impaired EDD in aging arteries ([@B40]; [@B51]) and by applying SIRT1 activator, the EDD was improved by partly reducing the oxidative stress ([@B51]).

An increase in stiffness of large elastic artery with age reduces the artery's ability to buffer increase in pressure churned out by systolic ejection ([@B36]). The type I collagen, a load-bearing protein in the arterial wall, is augmented during aging, while the main structural protein, elastin, diminishes in old arteries ([@B39]). Treatment using NMN also reduced the large elastic stiffness in aged mice by reversing the accumulation of whole-vessel type I collagen and enhancing arterial elastin ([@B36]). A recent study showed that the protective effects of NMN supplement on vascular function are associated with increased anti-aging miRNA expression profile in the aorta of aged mice ([@B89]).

The brain, which is, a metabolically active organ, relies on the blood circulation to deliver nutrients and eliminate metabolic waste products ([@B168]). Cerebromicrovascular health is critical for brain perfusion, which helps in the maintenance of healthy cerebral function. Adjustment in cerebral blood flow maintains cellular homeostasis and function through neurovascular coupling (NVC), in response to the increased neuronal activity ([@B168]). Microvascular endothelium releases the vasodilator (NO) in response to increased neuronal and astrocytic activation ([@B171]). Several lines of evidence suggest that NVC responses are impaired in the course of aging, hence contributing to age-related cognitive impairment ([@B171]; [@B8]). Emerging studies have revealed that an increase in mitochondrial oxidative stress and mitochondrial dysfunction results in impairment of neurovascular during the aging process ([@B158]).

A report by a recent study on aged mice showed that NMN could restore the function of cerebromicrovascular endothelium and NVC responses ([@B169]). NMN (i.p. 500 mg/kg) was injected in male aged mice (24 months old) for 14 consecutive days. The treatment restored the NO mediation of NVC in aged mice by reestablishing NO release, which resulted in endothelial NO-mediated vasodilation in the aortas of aged mice. The NO mediation of NVC responses is weakened by age-related mitochondrial oxidative stress. NMN increased the activation of SIRT1, which reversed mtDNA-encoded subunits, attenuated mtROS production, and improved mitochondrial bioenergetics. Thus, NMN can restore the protective effects of cerebromicrovascular by improving endothelial function, attenuating endothelial oxidative stress, and improving NVC responses in aged mice ([@B169]).

Age-related NAD+ depletion and consequential SIRT1 dysregulation are associated with impaired angiogenic processes in cerebromicrovascular. However, a study indicated that NMN could rescue angiogenic capacity in aged cerebromicrovascular endothelial cells (ECs) ([@B88]). Recently, the same team identified 590 genes differentially expressed in the aged neurovascular unit, 204 of which were shifted back toward youthful expression levels by NMN ([@B90]). NMN supplementation reverses age-related changes in neurovascular gene expression, including SIRT1 activation, mitochondrial protection, anti-inflammatory, and anti-apoptotic ([@B90]).

A steady decline in tissue perfusion has been observed in humans from the age of 40, which often results in organ dysfunction and general body weakness in the last decades of life ([@B97]). The number and function of ECs decline with age, resulting in increased apoptosis of ECs in the muscle, diminished neovascularization, and loss of blood vessels ([@B180]). These changes reduce muscle mass and endurance during aging ([@B137]). Abhirup et al. reported that SIRT1 in ECs is necessary for the response to pro-angiogenic signals secreted from myocytes and treatment with NMN improved blood flow and endurance in elderly mice by increasing capillary density ([@B34]). In the same study, the number and density of ECs and capillaries in skeletal muscle for endurance were significantly decreased in the old mice, which could have been associated with impaired angiogenesis. Endothelial-specific SIRT1 knockout mice (ESKO) exhibited the same phenotype of aging, including reduced density of capillaries and decreased exercise endurance. Overexpression of endothelial SIRT1 sensitizes ECs to vascular endothelial growth factor, which improves the muscle neovascularization and hence increases capillary density and endurance. Moreover, NAD+/SIRT1 negatively regulates Notch signaling ([@B62]), an indispensable signaling pathway for blood vessel formation ([@B13]).

Thus, NMN could restore angiogenesis in old mice through SIRT1-mediated inhibition of Notch signaling. NMN (400 mg/kg/day) was administered to old mice through drinking water for 2 months. The drug restored the number and density of capillaries, increased soluble oxygen (sO~2~) levels, and improved endurance in the old mice. However, these effects were abolished in SIRT1 knockout mice. Also, exogenous hydrogen sulfide (H~2~S) augmented the effect of NMN.

All these studies suggest that NMN could be a favorable agent for therapy against various diseases related to a decrease in blood flow brought about by cardiovascular dysfunction.

Intracerebral Hemorrhage {#S9}
========================

Intracerebral hemorrhage (ICH) is a primary brain injury resulting from mechanical damage that causes a hematoma. It can sometimes progress to a secondary injury, which is mainly subsequent pathophysiologic changes, including blood--brain barrier (BBB) destruction, hemoglobin-induced iron overload, neural cell death, neuroinflammation, and oxidative stress ([@B208]; [@B186]). A study suggested that NMN could be a promising agent for the treatment of ICH ([@B186]). A single dose of NMN (300 mg/kg) was injected into CD1 mice 30 min after treatment with collagen-induced intracerebral hemorrhage (cICH). The NMN treatment relieved the edema that had been induced by cICH and improved neurological function. Treatment using NMN reduced cell death and oxidative stress in hemorrhage area. Moreover, it suppressed the cICH-induced microglia activation and neutrophil infiltration and inhibited inflammatory-associated factors, including TNF-α and IL-6. The intercellular adhesion molecule-1 (ICAM-1) protein, an adhesion molecule, is essential for the process of neuroinflammation activation after ICH. The NMN treatment also inhibited an increase in ICAM-1 after cICH ([@B157]; [@B186]).

The secondary stage of ICH mainly results from toxicity caused by hemin, which is a breakdown product of hemoglobin. It causes cell death and induces extensive local inflammation/oxidative stress. Hemin can induce HO-1, a ubiquitous enzyme, which oxidatively cleaves pro-oxidant heme to produce biliverdin and carbon monoxide. NMN also elevates the nuclear Nrf2 protein expression to upregulate HO-1 protein expression in brain tissues, thereby inhibiting neuroinflammation and oxidative stress and contributing to the neuroprotection in ICH ([@B125]; [@B186]). Finally, a prolonged NMN treatment for 7 days significantly arrested body weight decline and neurological deficit caused by ICH.

Carrie et al. also reported that NMN supplement preserved mitochondrial function, mitigated inflammation, and increased survival rate in hemorrhagic shock ([@B155]). Lactic acidosis, which is a by-product of anaerobic metabolism, is used to estimate the success of resuscitation in injured patients ([@B17]). High lactate levels reflect tissue hypoperfusion, which is, in turn, related to the severity and survivability of the shock ([@B146]). Pretreatment (400 mg/kg/day for 5 days, oral) and resuscitation (400 mg/kg, intravenous) with NMN significantly reduced serum lactate levels during a fixed pressure hemorrhagic shock.

The NAD+ concentration in various tissue decreases rapidly with the severity of the injury during hemorrhagic shock ([@B190]), which can result in dysfunction of vital organs. Under hypoxic conditions, the mitochondrial electron transport chain becomes inefficient in reoxidizing NADH to the NAD ([@B187]). The NMN treatment can compensate for the decrease in NAD+ levels and preserved the NAD/NADH ratio in both kidneys and livers. Adenosine triphosphate reserves are also depleted following hemorrhagic shock and resuscitation, and NMN treatment also restores the reserves in the kidney, but, not the liver. This could be caused by elevated ATP consumption in the liver. Treatment with NMN preserves the impaired complex I--dependent (CI-dependent) respiration following hemorrhagic shock and resuscitation.

Hemorrhagic shock and resuscitation are usually accompanied by increased cytokine levels, oxidative stress, and insulin-resistant hyperglycemia, which indicates the existence of inflammation ([@B155]). Circulating levels of the cytokine IL-6 are as predictors of mortality in human patients ([@B161]). Treatment with NMN significantly reduces serum IL-6 cytokine levels and ameliorated shock-induced hyperglycemia. The most important is that NMN can enhance physiologic reserve and improve survival after hemorrhagic shock. Pretreatment with NMN increases the ability of animals to tolerate longer periods of hypoperfusion. Resuscitation with NMN significantly improves the survival.

Tissue plasminogen activator (tPA) is used for therapy in case of acute brain ischemia. The window of tPA therapy is within 0--4.5 h. A delayed tPA therapy dose not decrease infarction but worsens hemorrhagic transformation ([@B185]; [@B201]). [@B185] suggested that NMN could attenuate delayed tPA-induced hemorrhagic transformation after cerebral ischemia without changing tPA thrombolytic activity. In the study, delayed tPA therapy resulted in a high mortality rate in middle cerebral artery occlusion (MCAO) mice. However, a single dose of NMN (300 mg/kg) injection (i.p.) reduced the mortality rate. NMN also attenuated the delayed tPA-induced severe infarction volume and brain edema. The cerebral hemorrhage caused by delayed tPA was fatal, but NMN significantly decreased the cerebral hemorrhage and higher hemoglobin level in the ipsilateral hemisphere of delayed tPA mice. The administration of NMN also inhibited neural apoptosis and ameliorated microglial activation and reduced neuroinflammation in delayed tPA-treatment mice.

It has been reported that disruption of BBB could be a reason for tPA-induced hemorrhagic transformation ([@B86]). The tPA activates matrix metalloproteinases (MMPs), which destroys tight junction proteins (TJPs) ([@B144]). Consistent with previous findings, the protein levels of TJPs (claudins, occludin, and zonular occludens-1) were downregulated, and the activities of MMP9 and MMP2 were enhanced in delayed tPA treatment, which implied that the BBB integrity had been compromised. The NMN treatment significantly reversed these changes and protected BBB integrity. Thus, NMN could be a potential agent for the therapy of tPA-induced hemorrhagic transformation.

It was also reported that NMN is able to protect brain in both the early and the chronic phase of cryoinjury ([@B203]). These studies demonstrated that NMN could be a remedy for ICH of various causes.

Neuroprotective and Cognitive Function {#S10}
======================================

Cognitive decline is one of the many symptoms of aging, and regulation of adult neurogenesis could be a therapeutic strategy in overcoming the condition. There are two distinct populations of neural stem cells (NSCs) in the brain, which are found in the subgranular zone (SGZ) and subventricular zone (SVZ). They can self-renew and differentiate into transient amplifying progenitors, that is, neural stem/progenitor cells (NSPCs). The NSPCs undergo finite, lineage-restricted cell divisions to differentiate into the major cell types of the brain, such as neurons, oligodendrocytes, and astrocytes ([@B4]; [@B78]). Studies have revealed that aging is a negative regulator of NSPC proliferation, whereas NSPCs could be reactivated in the aged brain ([@B4]). Thus, restoring the function of NSPCs could effectively prevent age-associated cognitive decline.

Liana and Shin-ichiro established that, in response to insult-induced demyelination, NAMPT-mediated NAD+ biosynthesis was critical for NSPC self-renewal, proliferation, and differentiation into oligodendrocytes ([@B160]). The study found that levels of NAD+ and expression of NAMPT in hippocampus were declining with age. However, the long-term NMN administration was able to maintain the NSPC pool. Moreover, they found that NMN administration reduced defects in oligodendrogenesis caused by decrease in NAD+ levels. Thus, NMN could be a promising agent for maintaining the NSPC pool and reactivating NSPCs, which can improve remyelination caused by aging and neurodegenerative diseases ([@B160]). Also, [@B206] reported that NMN was able to induce NSC proliferation (via SIRT1 and SIRT2) and promote NSC differentiation (via SIRT1, SIRT2, and SIRT6).

Mental disorders such as anxiety are prevalent among older people and account for 10--20% of the total mental diseases in the population, most of which is dementia or major depressive disorder ([@B143]). Late-life anxiety disorder results in substantial financial burden on individuals and society. Sean et al. discovered that old mice developed cognitive hypersensitivity in response to aversive stimulation during contextual fear condition tests, which was associated with the age-related changes in emotionality and sensory processing ([@B81]). Moreover, specific knockdown of NAMPT in the hippocampal CA1 region recapitulated the same age-associated cognitive hypersensitivity, whereas dentate gyrus specific NAMPT knockdown mice did not show cognitive hypersensitivity.

Sean et al. found that calcium/calmodulin-dependent serine protein kinase (Cask), a crucial multidomain scaffold protein at the synapse and in cell junctions ([@B73]), is the downstream effector in response to the reduction in NAD+ and is also downregulated in the hippocampus during aging ([@B81]). Therefore, Sean et al. proposed a model to demonstrate that the levels of NAMPT and NAD+ in hippocampal neurons, particularly in CA1 neurons, decline during aging, leading to a decrease in SIRT1 activity and subsequent downregulation of Cask expression in the aged hippocampus. Cask interacts with the GluN2B subunit of *N*-methyl-D-aspartate receptor (NMDAR) for the transport of GluN2B-containing vesicles ([@B79]), and the reduction in Cask could cause dysfunction of GluN2B-containing NMDARs at the synapse, which could contribute to a wide range of cognitive and behavioral impairments during aging ([@B81]). The NMN supplementation, even in a short time, could reduce cognitive hypersensitivity and improve the sensory processing aspect of some aversive stimuli and possibly other related behaviors ([@B81]). Therefore, the NMN administration could prevent and treat such cognitive impairments and enhance the quality of life in old age.

NMN also prevented aging-induced cognitive impairment by improving cerebrovascular ([@B88]; [@B169]) and mitochondrial function, and reducing apoptosis in the prefrontal cortex and hippocampus of aged animals ([@B68]). [@B111] reported that NMN improved energy activity and survival rate in an *in vitro* model of Parkinson's disease. [@B47] also demonstrated that NR and NMN were able to normalize neuromuscular function and memory by regulation of mitophagy and enhancement of DNA repair in mice and worm models of ataxia-telangiectasia (AT), an autosomal recessive disease with progressive neurodegeneration.

A study indicated that NAMPT enzymatic activity enhancer P7C3 could have a neuroprotective effect in a mouse model of amyotrophic lateral sclerosis (ALS) ([@B170]), and the levels of iNAMPT in ALS patients were lower than those of age-matched controls ([@B182]). [@B182] silenced NAMPT in the projection neurons of adult mice and created Thy1-YFP-Nampt^--/--^ cKO mice that notably exhibited general motor abnormalities, muscle atrophy, progressive motor function deficits, and a shorter lifespan, some of which are the key features of ALS. Loss of NAMPT in projection neurons led to mitochondrial metabolic dysfunction and destroyed the mitochondrial homeostasis. Wang et al. reported that NAMPT knockdown disrupts the balance between mitochondrial fission/fusion and causes more fragmentation, which could lead to subsequent neuronal degeneration. The thy1-YFP-Nampt^--/--^ cKO mice exhibited neurodegeneration in the brain, especially in the motor cortex and increased acetylation proteins, which implied that NAD+-related perturbations induced a reduction in Sirt3 activity. Also, many lines of evidence have shown that increasing Sirt1 and Sirt3 deacetylation activities have a neuroprotective role in motor neuron degeneration diseases, such as ALS ([@B50]; [@B184]).

The thy1-YFP-Nampt^--/--^ cKO mice also showed widespread abnormalities of the neuromuscular junctions (NMJs), which is known to disrupt synaptic connectivity and cause defective synaptic transmission. Remarkably, NMN (400 mg/kg) treatment lessened disease severity, restored motor function, and extended the life span of Thy1-YFP-Nampt^--/--^ cKO mice. Recently, this same team reported that loss of NAMPT in projection neurons cause detrimental effects on the function and structure of NJM, including impaired synaptic vesicle cycling, morphological changes to the motor endplate, alterations of skeletal muscle contractile responses, and noticeable sarcomere misalignment ([@B112]). These detrimental effects were reverse by administration of NMN (400 mg/kg/day) for 14 days. However, NMN treatment did not restore skeletal muscle mitochondria morphology change caused by deletion of Nampt ([@B112]). Thus, NMN is a potential therapeutic drug for motor neuron (MN) degenerative diseases, including ALS. Increasing the NAD+ salvage pathway could reduce the symptoms of neurodegenerative diseases.

Alzheimer's Disease {#S11}
===================

AD is progressive dementia characterized by memory loss at an early stage of the disease progression. Currently, there is no effective therapy for AD treatment. Also, its molecular basis has not been elucidated ([@B57]). Thus, there is a need to focus on finding effective therapeutic drugs for the disease.

Mitochondrial dysfunction is a feature of many neurodegenerative diseases, including Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD) ([@B70]). Morphological and functional abnormalities of mitochondria may lead defects in the electron transport chain and ATP production, which are associated with AD ([@B70]; [@B110]). The NAD+ as a cofactor is crucial for the tricarboxylic acid cycle, mitochondrial oxidative phosphorylation, and glycolysis-related enzymatic reactions, and the levels of NAD+ in the cell are critical for neuronal survival ([@B108]). Thus, preventing NAD+ depletion and boosting cellular energy could be a therapy for neurodegenerative disease ([@B110]).

A study reported that NMN improved NAD+ catabolism and changed mitochondrial morphological dynamics in mice with AD ([@B110]). In the study, AD chimeric amyloid precursor protein APP~(swe)~/PS1~(ΔE9)~ double transgenic (AD-Tg) mice showed deficits in mitochondrial oxygen consumption rates (OCRs) in the brain and muscle at 3 months of age. The NMN (100 mg/kg) was subcutaneously injected to AD-Tg female and male mice consecutively for 28 days, which reversed mitochondrial OCR deficiencies in the AD model. Still, in the same study, full-length mutant human APP levels were significantly increased in the brain of AD-Tg mice compared to non-transgenic (NTG) mice. The administration of NMN decreased full-length mutant APP expression in AD-Tg mice. Immunoreactivity of SIRT1 and CD38 was also significantly increased in AD-Tg compared to NTG mice, which could be attributed to NAD+ catabolism. The AD mice pre-treated with NMN showed a lower SIRT1 immunoreactivity compared to Ag-TD mice, but still had a higher SIRT1 compared to NTG mice.

The mitochondrial morphology is vital for its functions, such as mitochondrial respiration and calcium homeostasis, among others. Fusion and fission are two fundamental processes in mitochondria, which are essential for cellular survival and disease vulnerability. The protection of the nervous system is associated with the fusion, and fission processes, both of which contribute to the damaged organelles' elimination ([@B44]). NMN administration increased the length of mitochondria and decreased fragmentation in the hippocampal sub-region ([@B110]). A study reported that NMN alters mitochondrial dynamics by SIRT3-dependent mechanism ([@B92]). Nina et al. also showed that the levels of the active form of fission protein, phosphorylated Drp1 (S616) (pDrp1), were significantly decreased in hippocampal mitochondria after a single-dose NMN treatment, and the same result was observed in AD-Tg mice ([@B110]). NMN also decreased the acetylation of mitochondrial proteins, such as mitochondrial SOD2, which is an important antioxidant enzyme and one of the targets of SIRT3. The SOD2 catalyzes superoxide into hydrogen peroxide and oxygen, which is then converted to water by glutathione peroxidase ([@B28]). Studies have shown that mitochondrial morphologies are associated with the generation of ROS, and the accumulation of ROS could induce more mitochondrial fragmentation ([@B188]). Thus, NMN treatment reduced hippocampal ROS through SIRT3-dependent deacetylation of SOD2, which resulted in lowering mitochondrial fragmentation via pDrp1 (S616).

The Aβ oligomers have been widely reported to be responsible for AD pathology. They usually accumulate in AD frontal cortex levels of up to 70-fold compared to normal brains ([@B57]). Wistar rats with an intracerebroventricular infusion of Aβ~1--42~ oligomer were used as AD mouse models. Intraperitoneal NMN (500 mg/kg) treatment improved their cognitive and memory functions, which might have been as a result of NMN reducing oxidative stress actions ([@B181]). Long-term potentiation (LPT), a mechanism for memory and learning functions, is significantly inhibited by Aβ oligomers, but NMN treatment was able to prevent this inhibition in organotypic hippocampal slice cultures (OHCs). Oxidative stress and a high concentration of ROS have toxic effects on synaptic transmission, which is essential in neurodegeneration ([@B63]). Administration of NMN prevented the accumulation of ROS induced by Aβ~1--42~ oligomer in OHCs, which could have been the reason for memory and learning improvement. The NMN treatment also attenuated the neuronal cell death and reduction of NAD+ and ATP in Aβ~1--42~ oligomer-treated hippocampal slices ([@B181]).

The c-Jun N-terminal kinases (JNKs) are a family of multifunction-signaling protein kinases that respond to various cellular stresses and inflammatory mediators ([@B116]). However, aberrant activation of JNK is associated with pathogenesis of Alzheimer's disease. A study demonstrated that NMN could reverse AD by inhibiting JNK activation in the hippocampus and cerebral cortex of AD-Tg mice ([@B195]). Administration of NMN ameliorated amyloid-induced synaptic loss and dysfunction, and reversed cognitive impairments in AD-Tg mice, including severe impairment of spatial learning, spatial memory and contextual memory.

Also, NMN decreased β-amyloid production and amyloid plaque burden ([@B195]). The NMN regulated the expression of APP cleavage secretase in AD-Tg mice, including elevation of sAPPα and reduction of sAPPβ. A previous study indicated that phosphorylation of APP on threonine 668 could promote β-secretase cleavage of APP, resulting in more Aβ generation ([@B32]). SIRT1 activation promoted non-amyloidogenic α-secretase processing of the amyloid precursor protein by inhibiting rho-associated kinase (ROCK1) expression ([@B138]). These results showed that NMN might enhance non-amyloidogenic APP processing and hence decrease Aβ pathology in AD-Tg mice. Neuroinflammatory, a crucial response for the development of AD ([@B121]), was shown to be inhibited by NMN treatment in AD-Tg mice ([@B195]), including decrease in IL-6, IL-1β, and TNFα. These proinflammatory cytokines stimulate β-secretase and γ-secretase to generate more Aβ in the brain through a JNK-dependent MAPK pathway ([@B106]). In conclusion, NMN improved cognitive abilities and decreased amyloid plaque, loss of synapse, β-secretase, and neuroinflammation, at least partially by inhibition of JNK activation.

These studies demonstrate that NMN could be a viable intervention for managing AD.

Retinal Degeneration and Corneal Injury {#S12}
=======================================

The photoreceptor is crucial for light transduction, which is necessary for vison, and there are two classes of photoreceptors: rods and cones. Rod and cone photoreceptors mediate dim and precise central vision in ambient light, respectively ([@B107]). Death of photoreceptors results in vision loss, and this occurs in many diseases, including age-related macular degeneration (AMD), retinitis pigmentosa (RP), and Leber congenital amaurosis (LCA) ([@B189]). It has been reported that mutations in NMNAT1 cause LCA, as a result of reduced NAD+ biosynthesis and impaired protein folding ([@B93]). Thus, NAD+ biosynthesis has a role in photoreceptor function and survival.

Knockout mice lacking Nampt in rod photoreceptors (Nampt^--rod/--rod^) and cone photoreceptors (Nampt^--cone/--cone^) showed a decreased retinal NAD+ level and a degenerative phenotype, including vascular attenuation, optic nerve atrophy, outer nuclear layer thickness reduction, and retinal function impairment ([@B107]). Retinal NAD+ deficiency was observed in multiple mouse models with retinal dysfunction, including light-induced degeneration, streptozotocin (STZ)-induced diabetic retinopathy, and aging-associated retinal dysfunction. NAD+ deficiency in photoreceptors causes significant glycolytic and mitochondrial dysfunction under basal conditions and impairs the normal response to moderate metabolic stresses, which results in photoreceptor cell death and retinal degeneration ([@B107]). Besides, photoreceptors are susceptible to defects in energy homeostasis because of their limited mitochondrial reserve ([@B94]). [@B107] demonstrated that SIRT3 and SIRT5 are both critical for photoreceptor survival and retinal homeostasis. It is through SIRT3 that NAD+ deficiency causes aberrant hyperacetylation of mitochondrial proteins, hence contributing to mitochondrial dysfunction.

Nampt is critical for energy metabolism in retinal cells and its deficiency results in impairment of retinal homeostasis. Downstream production of Nampt is a potential approach to relieve the impairment. Intraperitoneal injections of NMN (150 mg/kg) for 4 weeks improved scotopic and photopic retinal function and reduced photoreceptor death in Nampt^--rod/--rod^ and Nampt^--cone/--cone^ mice. Also, intraperitoneal injections of NMN (300 mg/kg) for 10 days were able to protect the retina from light-induced injury ([@B107]).

Mills et al. reported that long-term NMN administration ameliorated age-associated pathological changes in the eyes ([@B117]). The mutation in rd8 of C57BL/6N mice induced accumulation of subretinal microglia and macrophages with age, which was consistent with an increase in light-colored spots in the fundus of the eyes ([@B3]; [@B117]). The C57BL/6N mice at 17 months of age showed several light-colored spots in the fundus. However, the spots were significantly reduced in the fundus of the aged mice, which were on a long-term NMN supplementation. The long-term supplementation prevented rod cell dysfunction and improved scotopic b and photopic b waves in aged C57BL/6N, which suggested that the function of Muller/bipolar cell and cone cell was enhanced by NMN supplementation ([@B117]). The functioning of the lacrimal gland in humans and rodents gradually decreases with age ([@B209]). Notably, long-term NMN administration significantly increased tear production in aged mice ([@B117]).

The cornea is one of the most densely innervated tissues in the human body and corneal innervations play a critical role in the regulation of epithelial homeostasis ([@B14]). Neurotrophic keratopathy, a degenerative corneal disease with an impairment of trigeminal nerve, shows corneal epithelial defects, ulcer, and even perforation ([@B14]). Li et al. demonstrated that corneal denervation impaired the epithelial NAD+ levels by reducing the expression of NAMPT. This process led to deactivation of SIRT1, pAKR, and pCREB, and caused the apoptosis of corneal epithelial cells ([@B102]). NMN treatment significantly reduced the wound area and slowed down the corneal nerve fiber degeneration in the denervated mice. The supplement of NMN restored the activation levels of SIRT1, AKT, and CREB, and reversed the cell apoptosis and epithelial defects ([@B102]). A recent study also reported that subconjunctival injection of NMN or other NAD+ precursors effectively prevented ultraviolet B light (UVB)-induced tissue damage and EC apoptosis in the mouse cornea through reactivating AKT signaling ([@B205]). These findings demonstrate that NMN could be a therapeutic agent for treating diverse diseases that are associated with blindness.

Acute Kidney Injury (AKI) {#S13}
=========================

Approximately 1.33 million people worldwide suffer from AKI every year, resulting in a substantial economic and social burden on patients and society. The condition is associated with a high mortality rate exceeding 50% of those affected and the development of chronic kidney disease and other types of organ dysfunctions ([@B100]). Aging is an independent risk factor for AKI ([@B84]), and various age-related factors contribute to the increased susceptibility to AKI ([@B46]), including diabetes, hypertension, vascular diseases, and some iatrogenic factors ([@B84]).

Studies have revealed that SIRT1 and SIRT3 are critical in protecting the kidney from injury ([@B46]; [@B122]). Guan et al. reported that the administration of NMN could prevent age-associated susceptibility to AKI by restoring renal SIRT1 activity ([@B61]). The study found that kidneys of aged mice were more susceptible to cisplatin-induced AKI, and the NAD+ levels and SIRT1 expression were low in aged kidney. NAMPT and NMNAT were significantly lower in the kidney cortex of the old mice compared with those of the young mice. Four days of NMN treatment restored NAD+ levels in the kidneys and protected them from age-associated AKI. However, this protective effect of NMN was inhibited by SIRT1 deficiency, indicating that the renal protective effect of NMN was dependent on SIRT1. NMN treatment also protects the kidney from ischemia--reperfusion injury. Mice with NMN administration showed less ischemia--reperfusion injury and better kidney function compared with mice treated with PBS, which includes decreased blood urea nitrogen (BUN) and lower serum creatinine levels, and ameliorated tubular damage ([@B61]). Moreover, it has been shown that NMN could alleviate diabetic nephropathy nephritic fibrosis by inhibiting endogenous Nampt ([@B27]).

In conclusion, the findings of these studies show that NMN could be a potential therapeutic agent for AKI because of its ability to restore NAD+ and SIRT levels in the kidney.

Alcoholic Liver Disease {#S14}
=======================

As the most common chronic liver disease, alcoholic liver disease (ALD) is caused by chronic alcohol consumption and can develop from alcoholic fatty liver (AFL) to alcoholic steatohepatitis (ASH) ([@B154]). Ethanol-induced NAD+ depletion is involved in the development of ethanol-induced steatosis, oxidative stress, steatohepatitis, and insulin resistance ([@B113]). However, NMN treatment maintained the NAD+ levels and restored the alterations of TCA cycle metabolites that is induced by ethanol ([@B5]). NMN also successfully prevented an ethanol-induced increase in plasma levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), two damage biomarkers of liver. RNA-seq analysis revealed that ethanol changed the expression of 1778 genes, 25% of which were altered by NMN treatment ([@B5]). The mitogen-activated protein kinases (MAPK) pathway was one of the signaling pathways that were significantly affected by NMN. Previous studies have demonstrated that activating transcription factor 3 (Atf3) is associated with NAD+/NADH ratios and can be induced by ethanol ([@B119]). Elevated Atf3 also correlated with increased ALT and AST ([@B2]). Moreover, Atf3 overexpression has been found in patients with alcoholic steatohepatitis ([@B119]). Interestingly, NMN normalized extracellular signal-regulated kinase1/2 (Erk1/2) signaling and reduced the expression of Atf3 ([@B5]).

Other Diseases and Improvement of Physical Function {#S15}
===================================================

Associated with the loss of oocyte quality, reproductive aging in female mammals is an irreversible process that accompanies decreased levels of NAD+ ([@B10]). However, administration of NMN can hopefully restore oocyte quality and fertility in aged mice and reverse the adverse effect of maternal age on developing embryo, suggesting that NMN can rescue female reproductive function in mammals ([@B10]). Multigenerational obesity-induced perturbations in oocyte-secreted factor signal can also be normalized by NMN supplementation ([@B11]). However, NMN does not protect the ovarian reserve from radiotherapy and chemotherapy, such as γ-irradiation or cyclophosphamide ([@B163]).

Depression is a major mental health problem and has especially large effects on individual health and social burden. Previous studies have suggested that mitochondrial dysfunction and decreased ATP production contribute to depression ([@B1]). Recently, Xie et al. reported that in a corticosterone (CORT)-induced depressed mouse model, NMN could alleviate depression-like behaviors by improving mitochondrial energy metabolism via enhancing the activity of SIRT3 ([@B191]). Transcriptome and metabolome analysis demonstrated that NMN inhibited CORT-induced lipid synthesis, stimulated β-oxidation and glycolysis, and improved the TCA cycle to enhance ATP production in mitochondria.

Besides, NMN has also been reported to enhance skeletal muscle mitochondrial oxidative metabolism in aged mice ([@B56]), improve hepatic mitochondrial function in circadian mutant mice ([@B131]), reduce DNA damage, and protect against irradiation-induced alterations in white blood cell counts, lymphocytes, and hemoglobin ([@B101]). Recently, a study reported that NMN treatment improved mesenchymal stromal cells self-renewal with promoted osteogenesis and reduced adipogenesis via the SIRT1 pathway in aged and irradiated adult mice ([@B156]). Moreover, NMN supplement can alleviate aluminum-induced bone injuries via suppression of the thioredoxin-interacting protein (TXNIP)--NLRP3 inflammasome pathway ([@B104]). These findings further demonstrate that NMN can be used to treat a variety of diseases involving NAD+ decline ([Figure 4](#F4){ref-type="fig"} and [Table 1](#T1){ref-type="table"}).

![Nicotinamide mononucleotide ameliorates various diseases by increasing NAD+ levels in human. NMN is a promising molecule for therapy of diverse diseases, including diabetes, obesity, ischemia--reperfusion injury, heart failure, Alzheimer's disease, retinal degeneration, acute kidney injury, and so on.](fcell-08-00246-g004){#F4}

###### 

Therapeutic effects of NMN administration *in vivo.*

  Disease                                   Model                                                                                                                                                     Intervention                                                                                                                          Effects                                                                                                                                                                                                                           References
  ----------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------
  **Diabetes**                              Nampt-deficient heterozygous (Nampt ^+/--^) mice                                                                                                          NMN (i.p. 500 mg/kg) Single                                                                                                           Improved the defects in NAD biosynthesis and glucose-stimulated insulin secretion                                                                                                                                                 [@B145]
                                            Adenoviral-mediated hepatic overexpression of miR-34a in mice                                                                                             NMN (i.p. 500 mg/kg) 10 days                                                                                                          Improved glucose tolerance and increased expression of fatty acid β-oxidation genes                                                                                                                                               [@B30]
                                            Fructose-rich diet (FRD) mice                                                                                                                             NMN (i.p. 500 mg/kg) Single                                                                                                           Improved insulin secretion and protected against inflammation                                                                                                                                                                     [@B22]
                                            High-fat diet (HFD)-induced and age-induced diabetic mice                                                                                                 NMN (i.p. 500 mg/kg) HFD-induced diabetes (7--10 days) aged-induced diabetes 11 days                                                  Improved glucose tolerance and enhanced hepatic insulin sensitivity in HFD-induced diabetic mice. Improved glucose tolerance and lipid profiles in aged-induced diabetic mice                                                     [@B198]
                                            C57BL/6N mice                                                                                                                                             NMN (drinking water. 100, 300 mg/kg) 12 months                                                                                        Improved age-associated decreased insulin sensitivity and plasma metabolism                                                                                                                                                       [@B117]
                                            Aged beta cell-specific Sirt1 overexpression (BESTO) mice                                                                                                 NMN (i.p. 500 mg/kg) Single                                                                                                           Improved glucose tolerance and insulin secretion in the aged BESTO females                                                                                                                                                        [@B140]
  Obesity                                   Adipocyte-specific Nampt knockout (ANKO) mice                                                                                                             NMN (drinking water. 500 mg/kg) 4--6 weeks                                                                                            Improved multi-organ insulin sensitivity, increased adiponectin production and normalized plasma FFA concentrations                                                                                                               [@B164]
                                            Adipocyte-specific Nampt knockout (ANKO) mice                                                                                                             NMN (drinking water. 500--1000 mg/kg) 8 weeks                                                                                         Restored thermogenesis in ANKO mice, and normalized the expression of genes involved in thermogenesis, mitochondrial biogenesis, and FFA metabolism                                                                               [@B192]
                                            High-fat diet (HFD)-induced obese mice                                                                                                                    NMN (i.p. 500 mg/kg) 17 days                                                                                                          Improved glucose tolerance, liver citrate synthase activity, and reduced liver triglyceride content                                                                                                                               [@B174]
                                            HFD-consuming offspring of obese mothers                                                                                                                  NMN (i.p. 500 mg/kg) 18 days                                                                                                          Reduced adiposity and improved glucose tolerance and mitochondrial function                                                                                                                                                       [@B173]
                                            C57BL/6N mice                                                                                                                                             NMN (drinking water. 100, 300 mg/kg) 12 months                                                                                        Reduced age-associated body weight gain                                                                                                                                                                                           [@B117]
  Ischemia--reperfusion injury              Ischemia/reperfusion heart injury in C57BL/6J mice                                                                                                        NMN (i.p. 500 mg/kg) Once or 4 times                                                                                                  Reduced the infarct area and improved left ventricle (LV) systolic function after I/R                                                                                                                                             [@B193]
                                            Global cerebral ischemia in C57BL/6 mice                                                                                                                  NMN (i.p. 31.25, 62.5, 125, 250, and 500 mg/kg) Single                                                                                Reduced hippocampal CA1 neurons cell death and improved ischemia-induced hippocampal dysfunction involved in spatial working memory (62.5 mg/kg produced optimal treatment effects)                                               [@B130]
                                            Global cerebral ischemia in C57BL/6 mice                                                                                                                  NMN (i.p. 62.5 mg/kg) Single                                                                                                          Prevented post-ischemic depletion of mitochondrial NAD+, suppressed mitochondrial fragmentation, and reduced ROS generation                                                                                                       [@B91]
                                            Middle cerebral artery occlusion (MCAO) in Sprague-Dawley rats                                                                                            NMN (i.c.v. 10 mg/ml with 2 μl) Single                                                                                                Alleviated cerebral infarction size, neurological deficit, and neuronal cell death                                                                                                                                                [@B179]
                                            Middle cerebral artery occlusion (MCAO) in C57BL/6J mice                                                                                                  NMN (i.p. 500 mg/kg) 7 days with the first dose at 3 h (early) or 12 h (delayed) post MCAO                                            Alleviated brain infarction and neurological deficit, increased animal survival, and accelerated body weight recovery (early NMN administration). Improved post-ischemic regenerative neurogenesis (delayed NMN administration)   [@B206]
  Heart failure and cardiomyopathies        Cardiac-specific deletion of Ndufs4 (cKO) in mice                                                                                                         NMN (i.p. 500 mg/kg) twice in 3 days                                                                                                  Decreased the NADH/NAD+ ratio and mitochondria protein acetylation in cKO hearts, and normalized the sensitivity of the mitochondria permeability transition pore (mPTP)                                                          [@B85]
                                            Transverse aortic constriction (TAC)-stressed mice, cKO mice                                                                                              NMN (i.p. 500 mg/kg) 33 days (every 3 days)                                                                                           Suppressed mitochondrial protein hyperacetylation, improved cardiac function, and reduced pathologic hypertrophy induced by pressure overload                                                                                     [@B98]
                                            TCA in cardiac-specific deficiency of Klf4 (CM-K4KO) mice                                                                                                 NMN (i.p. 500 mg/kg) 5 days                                                                                                           Protected mice from pressure overload-induced heart failure, prevented cell death, preserved mitochondrial ultrastructure and reduced ROS in heart                                                                                [@B202]
                                            Cardiac-specific Fxn KO mice (FXN-KO) (Friedreich's ataxia cardiomyopathy model)                                                                          NMN (i.p. 500 mg/kg) 4--5 weeks (twice weekly)                                                                                        Improved diastolic function, normalized the defective cardiac contractility, improved cardiac energy utilization and decreased energy wastage and whole-body energy expenditure in FXN-KO mice                                    [@B115]
  Vascular dysfunction                      Aged (26--28 months) C57Bl/6 mice                                                                                                                         NMN (drinking water. 300 mg/kg) 8 weeks                                                                                               Improved artery endothelium-dependent dilation (EDD) and NO-mediated EDD, reduced arterial oxidative stress and large elastic artery stiffness                                                                                    [@B36]
                                            Aged (24-month-old) C57BL/6 mice                                                                                                                          NMN (i.p. 500 mg/kg) 14 days                                                                                                          Rescued neurovascular coupling (NVC) responses, and increased endothelial NO-mediated vasodilation                                                                                                                                [@B169]
                                            Aged (24-month-old) C57BL/6 mice                                                                                                                          NMN (i.p. 500 mg/kg) 14 days                                                                                                          Reversed age-related changes in miRNA expression profile in the aged mouse aorta                                                                                                                                                  [@B89]
                                            Aged (24-month-old) C57BL/6 mice                                                                                                                          NMN (i.p. 500 mg/kg) 14 days                                                                                                          Reversed age-related changes in neurovascular gene expression, including SIRT1 activation, mitochondrial protection, anti-inflammatory, and anti-apoptotic                                                                        [@B90]
                                            Aged (18-month-old) C57BL/6J mice                                                                                                                         NMN (drinking water. 400 mg/kg) 2 months                                                                                              Improved blood flow and endurance in elderly mice by increasing capillary density                                                                                                                                                 [@B34]
  Intracerebral hemorrhage                  Collagenase-induced intracerebral hemorrhage (cICH) in CD1 mice                                                                                           NMN (i.v. 300 mg/kg) Single (acute) NMN (i.v. and i.p. 300 mg/kg) 7 days (prolonged)                                                  Relieved the edema, improved neurological function, reduced cell death and oxidative stress, and inhibited neuroinflammation in cICH. Promoted the recovery of body weight and neurological function (prolonged administration)   [@B186]
                                            Hemorrhagic shock in Long--Evans rats                                                                                                                     NMN (400 mg/kg) Pretreatment (drinking water) for 5 days and during resuscitation with once (i.v.)                                    Inhibited inflammation, improved cellular metabolism, and promoted survival following hemorrhagic shock.                                                                                                                          [@B155]
                                            Tissue plasminogen activator (tPA)-treated CD1 mice with MCAO                                                                                             NMN (i.p. 300 mg/kg) Single                                                                                                           Prevented delayed tPA-induced brain damage, cerebral hemorrhage, neural apoptosis, and neuroinflammation, and protected blood--brain barrier integrity                                                                            [@B185]
  Neuroprotective and cognitive function    C57BL/6N mice                                                                                                                                             NMN (drinking water, 100, 300 mg/kg) 12 months                                                                                        Maintained the neural stem/progenitor cells (NSPCs) pool                                                                                                                                                                          [@B160]
                                            Aged (20-month-old) C57BL/6 mice                                                                                                                          NMN (p.o. 300 mg/kg) 3 weeks                                                                                                          Improved cognitive hypersensitivity (age-related changes in sensory processing and emotionality) in old mice                                                                                                                      [@B81]
                                            Aged (24-month-old) C57BL/6 mice                                                                                                                          NMN (i.p. 500 mg/kg) 14 days                                                                                                          Improved cognitive function in aged mice                                                                                                                                                                                          [@B169]
                                            Aged (24-month-old) Wistar rats                                                                                                                           NMN (i.p. 100 mg/kg) every other day for 28 days                                                                                      Alleviated aging-induced cognitive impairment, improved learning and memory in aged animals                                                                                                                                       [@B68]
                                            Projection-neuron-specific and inducible Nampt conditional knockout (Thy1-YFP-Nampt^--/--^ cKO) mice                                                      NMN (i.p. 400 mg/kg) Started on day 11 post- tamoxifen administration                                                                 Alleviated disease severity, restored motor function, and prolonged the lifespan                                                                                                                                                  [@B182]
                                            Thy1-YFP-Nampt^--/--^ cKO mice                                                                                                                            NMN (i.p. 400 mg/kg) 14 days                                                                                                          Reversed the detrimental effects on vesicle cycling, endplate morphology and muscle contractility                                                                                                                                 [@B112]
                                            Ataxia-telangiectasia mutated (ATM)-deficient mice (Atm^--/--^ mice) (Ataxia telangiectasia mouse model)                                                  NMN (drinking water, 12 mM) 2 weeks                                                                                                   Restored deficit in motor function and improved memory in Atm^--/--^ mice                                                                                                                                                         [@B47]
  Alzheimer's disease                       APP~(swe)~/PS1~(ΔE9)~ double transgenic (AD-Tg) mice                                                                                                      NMN (s.c. 100 mg/kg) every other day for 28 days                                                                                      Increased mitochondrial function and decreased amyloid precursor protein (APP) expression                                                                                                                                         [@B110]
                                            C57BL/6 mice and neuron-specific expression of mitochondria-targeted enhanced yellow fluorescent protein (mito-eYFP) transgenic mice                      NMN (i.p. 62.5 mg/kg) Single                                                                                                          Inhibited mitochondrial fission, decreased mitochondrial protein acetylation, and reduced ROS in the hippocampus                                                                                                                  [@B92]
                                            Intracerebroventricular infusion of Aβ~1--42~ oligomer in Wistar rats                                                                                     NMN (i.p. 500 mg/kg) 10 days                                                                                                          Improved cognitive function                                                                                                                                                                                                       [@B181]
                                            APP~(swe)~/PS1~(ΔE9)~ double transgenic (AD-Tg) mice                                                                                                      NMN (s.c. 100 mg/kg) every other day for 28 days                                                                                      Improved cognitive abilities and decreased amyloid plaque, loss of synapse, β-secretase, and neuroinflammation                                                                                                                    [@B195]
  Retinal degeneration and corneal injury   Rod-specific Nampt KO mice (Nampt^--rod/--rod^) Cone-specific Nampt KO mice (Nampt^--cone/--cone^) Light-induced retinal dysfunction (129S1/SvlmJ mice)   NMN (i.p. 150 mg/kg) 4 weeks for Nampt^--rod/--rod^ and Nampt^--cone/--cone^ mice NMN (i.p. 300 mg/kg) 10 days for 129S1/SvlmJ mice   Prevented photoreceptor degeneration and improved vision in Nampt^--rod/--rod^ and Nampt^--cone/--cone^ mice. Protected the retina from light-induced injury in 129S1/SvlmJ mice                                                  [@B107]
                                            C57BL/6N mice                                                                                                                                             NMN (drinking water, 100, 300 mg/kg) 12 months                                                                                        Ameliorated age-associated pathological changes in the eyes, and increased tear production in aged mice                                                                                                                           [@B117]
                                            Corneal denervation in C57BL/6 mice                                                                                                                       NMN (251 ng/eye) subconjunctival injection 2 days                                                                                     Reduced wound area and slowed down the corneal nerve fibers degeneration in the denervated mice                                                                                                                                   [@B102]
                                            Ultraviolet B light (UVB)-induced injury in C57BL/6 mice                                                                                                  NMN (500 mM, 5 μl/eye) subconjunctival injection 2 days                                                                               Prevented ultraviolet B light (UVB)-induced tissue damage and endothelial cell apoptosis in the mouse cornea                                                                                                                      [@B205]
  Acute kidney injury (AKI)                 Cisplatin-induced AKI or ischemia reperfusion injury in 129S2/Sv mice, and C57BL/6 mice                                                                   NMN (i.p. 500 mg/kg) 4 days                                                                                                           Protected renal function from cisplatin-induced AKI and ischemia reperfusion injury                                                                                                                                               [@B61]
  Alcoholic liver disease (ALD)             Lieber--DeCarli chronic ethanol model in C57BL/6 J mice                                                                                                   NMN (i.p. 500 mg/kg) every other day for 6 weeks                                                                                      Prevented an ethanol-induced increase in plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST), and changed the gene expression that were modulated by ethanol                                               [@B5]
  Other diseases                            C57BL6/JAusb mice                                                                                                                                         NMN (drinking water, 0.5 and 2 g/L) for 4 weeks                                                                                       Restored oocyte quality and enhanced ovulation rate and fertility in aged mice                                                                                                                                                    [@B10]
                                            HFD-consuming offspring of obese mothers                                                                                                                  NMN (i.p. 500 mg/kg) 18 days                                                                                                          Ameliorated multigenerational obesity-induced perturbations in oocyte-secreted factor signal                                                                                                                                      [@B11]
                                            Corticosterone (CORT)-induced depression in C57BL/6 mice                                                                                                  NMN (p.o. 300 mg/kg) 2 weeks                                                                                                          Alleviated depression-like behaviors                                                                                                                                                                                              [@B191]
                                            C57BL/6J                                                                                                                                                  NMN (i.p. 500 mg/kg) 7 days                                                                                                           Enhanced skeletal muscle mitochondrial oxidative metabolism in aged mice                                                                                                                                                          [@B56]
                                            Bmal1 KO mice                                                                                                                                             NMN (i.p. 250 mg/kg). Single NMN (i.p. 500 mg/kg) 10 days                                                                             Increased hepatic mitochondrial respiration                                                                                                                                                                                       [@B131]
                                            Old C57BL/6J mice and young irradiated C57BL/6J mice                                                                                                      NMN (i.p. 500 mg/kg) 7 days. NMN (p.o. 2000 mg/kg) 8 days                                                                             Reduced DNA damage and protected against irradiation-induced changes in white blood cell counts, lymphocytes, and hemoglobin                                                                                                      [@B101]
                                            Aged C57BL/6J (12-month-old) mice, and sublethal irradiation in adult (2-month-old) C57BL/6J mice                                                         NMN (drinking water. 300 mg/kg) 3 months                                                                                              Stimulated osteogenesis of endogenous mesenchymal stromal cells (MSCs), and protected bone from aging and irradiation induced damage in mice                                                                                      [@B156]
                                            AlCl~3~-treated Sprague--Dawley rats                                                                                                                      NMN (i.p. 20 mg/kg) 4 weeks                                                                                                           Alleviated aluminum-induced bone loss                                                                                                                                                                                             [@B104]
                                            Brain cryoinjury in Balb/c mice                                                                                                                           NMN (i.c.v. 5 mM with 7 μl) Single                                                                                                    Protected brain in both the early and the chronic phase of cryoinjury                                                                                                                                                             [@B203]
                                            Adipocyte-specific Nampt knockout (ANKO) mice                                                                                                             NMN (i.p. 500 mg/kg) Single                                                                                                           Restored physical activity in ANKO mice                                                                                                                                                                                           [@B196]

IP, intraperitoneal; IV, intravenous; PO, per oral; SC, subcutaneous; ICV, intracerebroventricular.

Possible Detrimental Effects of NMN Supplementary {#S16}
=================================================

Although the benefits of NMN are obvious, some studies suggest that people need to use it with caution. Keeping NMN at a low level was beneficial to the axon survival ([@B37]). NMN accumulation could promote Wallerian or Wallerian-like degeneration, which was involved with the physical neurite injury. Inhibiting NAMPT or maintaining NMNAT activity could preserve the structure and function of the transected axons and the distal axon stump by preventing the increase of NMN. It is worth noting that since a long-term NAD+ depletion would become harmful for protection of axons, a time window of inhibiting the NMN accumulation was shown after the acute injury ([@B38]). To decrease the level of NMN and maintain the production of NAD+, nicotinic acid riboside (NAR) was introduced in treating chemotherapy-induced axon degeneration by generating NAD+ through an alternative pathway that bypassed NMN formation ([@B109]).

It was reported that a lower dosage of NMN could be more effective and safer, for example, the brain may be more sensitive to the concentration of NMN ([@B130]). A lower-dose administration of NMN resulted in improved female infertility with enhanced oocyte quality. Overdose of NMN may have some adverse effects on other aspects of fertility ([@B10]). NMN administered by intraperitoneal injection increased oxidative stress of sperm and reduced sperm quality in male offspring of obese mothers with HFD, whereas oral administration of NMN did not have these effects ([@B200]). These data indicated that the effects of NMN were complex and the therapeutic dose or mode of administration needs more investigation in the future.

Carefully, NAD turnover in tumor cells is higher than nontumor cells. The expression levels of NAMPT were found to be elevated and have a positive relationship with the stage of tumor progression in many types of tumor, indicating that downregulation of NAMPT/NAD+ may become a strategy for anti-cancer therapy ([@B178]; [@B64]). It is noteworthy that SIRT1, as downstream targets, has both tumor-suppressor and oncogenic roles under different circumstances ([@B25]). Thus, efficiency and long-term safety of NMN should be precisely assessed in further preclinical and clinical studies.

Human Clinical Study {#S17}
====================

Given that NMN has shown high efficacy and benefits in various mouse models of human disease, several clinical trials of NMN have been conducted to investigate its clinical applicability ([Table 2](#T2){ref-type="table"}). This has led to some capsule formulations of NMN being approved and put on the market as health supplements ([@B134]).

###### 

Human clinical trials of NMN.

  Molecule   Objectives                                                                                                      Subjects and sample size                                                   Intervention                              Study design                                   Region and Institute                                                   Phase                    Trial number
  ---------- --------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ----------------------------------------- ---------------------------------------------- ---------------------------------------------------------------------- ------------------------ ---------------
  NMN        Evaluate the safety and kinetics of NMN in healthy volunteers                                                   Healthy men 40--60 years (*n* = 10)                                        NMN P.O. single time                      Non-randomized non-label uncontrolled          Keio University School of Medicine in Japan                            I                        UMIN000021309
  NMN        Evaluate the safety and kinetics of long-term NMN and its effect on glucose metabolism in healthy volunteers.   Healthy men 40--60 years (*n* = 30)                                        NMN P.O. 8 weeks                          Non-randomized non-label uncontrolled          Keio University School of Medicine in Japan.                           II                       UMIN000030609
  NMN        Evaluate the effect of the dietary (NMN) on key cardiovascular and metabolic functions in healthy women.        Postmenopausal women pre-diabetic BMI 25.0--44.9 55--75 years (*n* = 25)   Placebo or 250 mg/day NMN P.O. 8 weeks    Randomized double-blinded placebo-controlled   Washington University School of Medicine in United States of America   Active, not recruiting   NCT03151239
  NMN        Evaluate the safety and effect of long-term NMN on various hormonal levels in healthy human.                    Healthy men and women 50--70 years (*n* = 20)                              100 or 200 mg/day NMN P.O. 24 weeks       Randomized double-blinded dose comparison      Hiroshima University in Japan                                          Not applicable           UMIN000025739
  NMN        Evaluate the effect of NMN on the body composition in the elder                                                 Healthy men no smoking BMI 22--28 ∼65 years (*n* = 42)                     Placebo or 250 mg/day NMN P.O. 12 weeks   Randomized double-blind placebo-controlled     The University of Tokyo Hospital in Japan                              Not applicable           UMIN000036321

The first phase I human clinical study (UMIN000021309) for NMN has been initiated by an international collaborative team between Keio University School of Medicine in Tokyo and Washington University School of Medicine in St. Louis. The aim of this study is to examine the safety and bioavailability of NMN in human bodies. This research is led by Hiroshi Itoh, a professor of Endocrinology, Metabolism and Nephrology, Tokyo and Shin-ichiro Imai, a professor of Developmental Biology, at Washington University ([@B172]). Recently, they reported that a single oral administration of NMN up to 500 mg was safe and effectively metabolized in healthy subjects without causing severe adverse events. The major final metabolites of NMN were significantly increased in a dose-dependent manner by NMN administration. However, the team failed to detect NMN in plasma samples in this study. In a further study, they will detect the levels of NMN in plasma and NAD+ in peripheral blood mononuclear cells ([@B77]).

Itoh is also conducting a phase II study (UMIN000030609) to assess the safety of long-term NMN in healthy subjects, the kinetics of NMN and metabolites of NAM, and the effect of daily administration of NMN on glucose metabolism. Other clinical trials of NMN are ongoing at Washington University to examine the effect of NMN on insulin sensitivity, endothelial function, blood lipids, body fat and liver fat, and fat tissue and muscle tissue markers of cardiovascular and metabolic health. Additionally, a study (UMIN000025739) has been initiated at Hiroshima University, Institute of Biomedical and Health Sciences to evaluate the effect of long-term oral administration of NMN on various hormones in healthy volunteers. Recently, a new clinical study (UMIN000036321) was initiated at the University of Tokyo Hospital to evaluate the effect of NMN oral administration on the body composition in elderly persons.

In summary, despite the tremendous research efforts aimed at exploiting the therapeutic potential of NMN to treat metabolic and aging-related diseases, the clinical and toxicological evidence to support its utility is currently insufficient ([@B134]). Thus, further research is needed to increase the prospects of developing drugs based on NMN.

Perspective {#S18}
===========

Among various NAD+ precursors, NMN and NR seem to increase NAD levels more effectively than NAM in rodents ([@B139]). Since NAM acts as a feedback inhibitor to suppress sirtuins and PARPs, the benefits of increase in NAD+ levels may be compromised ([@B12]). Additionally, because of the shorter resident time, high-dose administration, and some side effects of NAM, it was not the preferred choice compared with NMN and NR ([@B87]).

It is difficult to compare NMN with NR, both of which are subjected to first-pass metabolism and the quick conversion to other NAD+ intermediates before uptake *in vivo* ([@B48]; [@B141]). NR, instead of NMN, is unstable and quickly converted into NAM in murine plasma ([@B141]). Some differences regarding the pharmacological effects of NMN and NR should be noted. As mentioned above, NMN improves cardiac function in a SIRT3-dependent manner in an FRDA cardiomyopathy model ([@B115]), whereas NR does not ([@B162]). Exploring the pharmacokinetics of NMN and NR *in vivo* could help determine the optimal concentration of them in different regions and facilitate understanding the mechanisms of their pharmacological actions. Head-to-head study should be performed to compare NMN and NR in the future.

Besides making a choice between NMN and NR, more precise data about the dosage and more detailed mechanism are needed. Some researches attempted to utilize novel methods to achieve integral understanding ([@B5]; [@B90]; [@B191]). In order to understand the complex NMN-related network changes, high-throughput methods are indispensable, such as methylation profiling, transcriptome, proteome, and metabolomics. In addition, the multifunctional role of NAD+ indicates that NAD+ might function in various organelles. It would be intriguing to decipher NAD+-related mechanism in subcellular compartment.

Further researches are compelling to reveal links between NAD+-related pathway and other disease-related pathway. More importantly, efficiency and safety should be precisely assessed in NMN clinical application.

Conclusion {#S19}
==========

NAD+ metabolism has been proven to be an essential part of biochemical reaction that acts as a link between various physiologic processes. During aging, weakened NAD+ biosynthesis and accelerated NAD+ consumption lead to dysfunction in multiple tissues. Depressed NAD+ levels disturb many biochemical processes, for instance, abnormal deacetylation activity of sirtuins. Downstream alterations of abnormal sirtuin activity include transcription pattern, mitochondrial permeability, mtROS production, and oxidative stress response. As an intermediate in NAD+ biosynthesis, NMN is a promising agent to reinforce NAD+ metabolism and alleviate age-related pathologic processes *in vivo*, which has promoted NMN to stage of clinical trial. More details of NAD+ metabolism pathway and applications of NMN are fascinating for further researches.
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